Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers

Mutations in TP53 induce autoantibody immune responses in a subset of cancer patients, which have been proposed as biomarkers for early detection. Here, we investigate the association of p53‐specific autoantibodies with multiple tumor subtypes and determine the association with p53 mutation status and epitope specificity.

[1]  K. Anderson,et al.  Autoantibodies in cancer: prognostic biomarkers and immune activation , 2011, Expert review of proteomics.

[2]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[3]  K. Vousden,et al.  p53 mutations in cancer , 2013, Nature Cell Biology.

[4]  Marc E. Lenburg,et al.  Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) , 2011, Breast Cancer Research and Treatment.

[5]  Yanhui Hu,et al.  Next generation high density self assembling functional protein arrays , 2008, Nature Methods.

[6]  P. Laurent-Puig,et al.  Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. , 1993, Cancer research.

[7]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[8]  T. Soussi,et al.  p53 Antibodies in the sera of patients with various types of cancer: a review. , 2000, Cancer research.

[9]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[10]  Joshua Labaer,et al.  Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. , 2011, Journal of proteome research.

[11]  Joshua Labaer,et al.  p53 Autoantibodies as Potential Detection and Prognostic Biomarkers in Serous Ovarian Cancer , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[12]  K. Eguchi,et al.  Measurement and evaluation of serum anti-p53 antibody levels in patients with lung cancer at its initial presentation: a prospective study. , 1998, British Journal of Cancer.

[13]  U Menon,et al.  Early detection of cancer in the general population: a blinded case–control study of p53 autoantibodies in colorectal cancer , 2012, British Journal of Cancer.

[14]  Thierry Soussi,et al.  The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis , 2012, Nucleic Acids Res..

[15]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[16]  A. Fersht,et al.  The tumor suppressor p53: from structures to drug discovery. , 2010, Cold Spring Harbor perspectives in biology.

[17]  J. Greenman,et al.  Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer. , 2013, World journal of gastroenterology.

[18]  Carol Prives,et al.  Mutant p53: one name, many proteins. , 2012, Genes & development.

[19]  E. Reinherz,et al.  The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays. , 2009, Vaccine.

[20]  L. Quéro,et al.  Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy , 2012, BMC Cancer.

[21]  N. Wentzensen,et al.  A systematic review of humoral immune responses against tumor antigens , 2009, Cancer Immunology, Immunotherapy.

[22]  T. Hupp,et al.  Drug discovery and mutant p53. , 2010, Trends in cell biology.

[23]  K. Anderson,et al.  Rapid detection of antibodies in sera using multiplexed self-assembling bead arrays. , 2009, Journal of immunological methods.

[24]  G. Wallstrom,et al.  A versatile protein microarray platform enabling antibody profiling against denatured proteins , 2013, Proteomics. Clinical applications.

[25]  Joshua LaBaer,et al.  Nucleic acid programmable protein array a just-in-time multiplexed protein expression and purification platform. , 2011, Methods in enzymology.

[26]  Joshua LaBaer,et al.  Autoantibody Signature for the Serologic Detection of Ovarian Cancer , 2014, Journal of proteome research.

[27]  R. Hamelin,et al.  Correlations between p53‐protein accumulation, serum antibodies and gene mutation in colorectal cancer , 1999, International journal of cancer.

[28]  D. Cahill,et al.  Assessment of the humoral immune response to cancer. , 2012, Journal of proteomics.

[29]  H. Juhl,et al.  Detection of the anti-p53 antibody response in malignant and benign pancreatic disease. , 1994, British Journal of Cancer.

[30]  M. Tomita,et al.  Monoclonal antibodies based on hybridoma technology. , 2013, Pharmaceutical patent analyst.

[31]  P. Laurent-Puig,et al.  Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. , 1995, Gut.

[32]  W. Caspary,et al.  p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma. , 1996, Pancreas.

[33]  D. Cahill,et al.  Epitope presentation is an important determinant of the utility of antigens identified from protein arrays in the development of autoantibody diagnostic assays. , 2012, Journal of proteomics.

[34]  Dina Aronzon,et al.  Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. , 2008, Journal of proteome research.